Healthcare Data Monetization: A Guide for Providers

Healthcare data monetization means earning value from the health data your organization already holds. For hospitals, clinics, laboratories and imaging centers, the most direct route today is licensing de-identified data to companies that build AI. This guide explains what that involves, how HIPAA de-identification works and how to prepare before you talk to anyone.

This is general information, not legal advice. Your privacy officer and legal counsel decide what your organization can do.

What is healthcare data monetization?

There are two kinds of data monetization in healthcare.

• Indirect monetization uses data inside your organization. You analyze records to cut costs, reduce readmissions or plan staffing. The value shows up as savings.
• Direct monetization brings in outside revenue. You license data, or access to it, to another organization under a contract.

AI licensing is the direct route. AI developers need real clinical records to train and test models. Public web data rarely contains documented lab results, imaging studies or follow-up over time. Healthcare providers hold exactly that.

Some institutions already run formal programs. Stanford AIMI explains how commercial companies can license its shared medical datasets. The University of Michigan publishes its own data licensing process, with review steps before any agreement.

Licensing is not the same as selling. With a license, you keep ownership. The contract sets who can use the data, for what purpose, for how long and under which security rules.

Which healthcare data do AI companies look for?

AI teams value records that show what was observed, what was decided and what happened next. Start with one archive your team knows well. The table shows common examples. It is illustrative, not a list of current buyer requests.

Organization	Archive	Why it can be useful	What to document
Hospital or clinic group	Encounters with follow-up	Shows care decisions and later outcomes	Which follow-up the system actually records
Diagnostic laboratory	Orders, results and amended reports	Structured, coded and high in volume	Methods, units, reference ranges and corrections
Imaging center	Studies linked to radiology reports	Pairs images with expert text	Modality, report status and the link between study and report
Pathology group	Reports and slide archives	Expert findings on tissue samples	Specimen context and review status
Specialty clinic	Repeated measurements over time	Shows how conditions change	Visit intervals and gaps in follow-up

Two cautions apply. First, an image archive and a report archive are different assets. A report that mentions a finding does not mean the image is available. Second, a missing follow-up entry means the outcome was not recorded. It does not mean the patient recovered.

Our healthcare datasets page covers these record types in more detail. Clinical-trial and drug development data have their own rules; see pharmaceutical data.

5 ways providers can prepare

1. Pick one archive. Choose a record family your team understands, such as imaging studies with final reports. Do not start with “all our data.”
2. Write an archive profile. Describe the record types, the rough time span, the systems that hold them and the known gaps. Leave out patient records and examples.
3. Find the decision makers early. Name a sponsor and bring in privacy, legal, clinical governance and IT. A keen clinician or database administrator cannot approve a license alone.
4. Check contracts and consents. Review vendor agreements, research protocols, patient notices and data-sharing terms. Some of them may limit what you can license.
5. Agree on a de-identification route. Decide with counsel whether Safe Harbor or Expert Determination fits, or whether the data should not be shared at all. Settle this before anyone extracts records.

How does HIPAA de-identification work?

In the United States, health data held by covered entities is protected health information (PHI) under HIPAA. De-identified health information is not PHI, so the HIPAA Privacy Rule no longer restricts it. The rule allows two ways to de-identify data. Both are set out in 45 CFR 164.514, and HHS guidance explains them.

Safe Harbor

You remove 18 listed types of identifiers about the patient and their relatives, employers and household members. They include names, geographic detail smaller than a state, all date elements except the year, phone numbers, email addresses, record numbers and full-face photographs. You must also have no actual knowledge that the remaining data could identify someone.

Safe Harbor is easy to explain and to check. It also removes detail, such as exact dates, that some AI projects need.

Expert Determination

A qualified expert applies statistical or scientific methods. The expert concludes that the risk of identifying a person is very small and documents the methods and results. This route can keep more useful detail, such as shifted dates or broad locations. It takes more work. The finding applies to a specific dataset and setting, so it may need to be redone if those change.

A limited data set is still PHI

A limited data set removes direct identifiers but can keep dates and some location data. It is still PHI. It may be used only for research, public health or health care operations, and only under a data use agreement. It is not a shortcut to commercial AI licensing.

Two more points. Removing names alone does not de-identify data, and calling a project research does not settle permission. HIPAA also restricts the sale of PHI: in general it needs the patient’s authorization. See 45 CFR 164.502 and 45 CFR 164.508. HHS research guidance covers research uses separately.

Outside the United States

• EU and EEA. The European Commission explains that pseudonymised data that can still be used to re-identify a person remains personal data under the GDPR. A US “de-identified” label does not settle the question in Europe.
• United Kingdom. Health data is special category data. The ICO says you need both a lawful basis under Article 6 and a separate condition under Article 9.
• Other countries. Check local law for where the data was collected, where it will be processed and who will receive it.

Who must approve it inside your organization?

A licensing project touches several teams. Expect to involve:

• An executive sponsor who owns the decision and the relationship.
• Privacy and compliance, to choose the de-identification route and confirm the legal basis.
• Legal counsel, to review existing contracts and negotiate the license.
• Clinical governance or the research office, to judge ethical fit and any review board questions.
• IT and data teams, to describe the systems and, later, run the extraction.
• Information security, to approve how data would be delivered and stored.

Our data licensing principles set out what we will and will not do. Our security page explains how we handle information during a review.

What does a first conversation look like?

A first conversation uses descriptions, not records. You tell us the organization type, country, broad record categories, rough years of history and what still needs review. No patient data is needed.

We then check whether AI developers are looking for that kind of data, and which rights and privacy questions need answers. If it fits, we work with your team on preparation and licensing. There is no fee to the data owner; our compensation comes out of the license. The full process is on how it works.

Hold other kinds of business data too? Our guide on how to sell data to AI companies covers the wider picture, and for data owners explains how we work with organizations in any sector we cover.

Ready to start? Describe your healthcare archive. We reply within 24 hours. No license is guaranteed.